Press Release Vascarta Outlines Proposed Mechanistic Link Between VAS-101’s (Vasceptor®) Vascular and Red Blood Cell Effects in Sickle Cell Disease 1 hour ago
Press Release Vascarta Announces NIH Phase I clinical study of VAS-101 in sickle cell disease begins Aug 19